Research and Markets: World Market for Cancer Diagnostics: Precision and Personalized Testing Arrives
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/fr333h/the_world_market) has announced the addition of the "The World Market for Cancer Diagnostics, 5th Edition: Precision and Personalized Testing Arrives" report to their offering.
“The World Market for Cancer Diagnostics, 5th Edition: Precision and Personalized Testing Arrives”
Cancer testing is maturing from personalized medicine to precision medicine, where protein and molecular biomarkers are essential for precise diagnosis, therapy selection, therapy monitoring and early detection of cancer recurrence. The market for cancer testing are comprehensively covered in Worldwide Market for Cancer Diagnostics, 5th. Edition.
This report contains detailed market data on the following IVD segments for their use in cancer diagnostics:
- Flow Cytometry
- Rapid Tests
- Molecular Assays
- Tissue Arrays
- Circulating Tumor Cells
- Pharmacodiagnostics, Molecular
Cancer Testing: Constant Innovation
- Given the unfortunate statistics of cancer in the developed world, innovation is a must. Growth rates in cancer testing tends to be higher than in other IVD fields. Diagnostic tests for effective cancer screening are obviously needed more than ever. As this report goes to print a number of significant developments are taking place in cancer follow up.
- New imaging modalities and digital analysis of x-ray mammograms are looking to improve the accuracy of breast cancer screening. These same imaging techniques are being used to screen patients for the metastasis of cancer from the primary site.
- Lab testing for new cancer biomarkers - hormone, receptor and protein assays - improve the detection of cancer in patients that present with symptoms. These are now available in multiplexed tests that make better use of tissue samples.
- With developments in the analysis of circulating cancer cells and cell free DNA in peripheral blood they are poised to help in the screening of high risk individuals.
- Improved immunohistochemical stains and in situ hybridization make detection of cancer cells in biopsied tissue more effective. The use next generation analysis of individual tumor cells including sequencing, mass spectrometry and PCR further enhance cancer testing in tissues.
- Bioinformatic analysis of gene and protein patterns detected in tumor cells and peripheral blood is proving to be a big breakthrough in cancer diagnosis. The technology has pinpointed gene and protein targets that will make up the next generation of cancer tumor marker panels.
- The next big advances are related to tests based on the detection of circulating nucleic acid molecules and RNA and DNA methylation patterns.
Some of the trends examined in this report include:
- Commercializing Next Generation Cancer Tests
- Clinical Molecular Test Reimbursement Coding In The U.S.
- Regulatory Requirements of Cancer Tests
- Gene Patents and Test Commercialization
- The Physician's Role in Test Acceptance
- Biomarkers: Issues in Research to Clinic
- Miniaturization and Multiplexed Assays
- The Emergence Of Non-Invasive Tools
- Bioinformatics's Data To Information
- Digital PCR, Mass Spectrometry, Next-Generation Sequencing
- Sample Preparation and System Automation
- The Role of In Vivo Cellular and Molecular Imaging
- Analyst Conclusions, Strategy Implications and Unmet Market Needs
For more information visit http://www.researchandmarkets.com/research/fr333h/the_world_market